CL2015000559A1 - Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. - Google Patents
Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras.Info
- Publication number
- CL2015000559A1 CL2015000559A1 CL2015000559A CL2015000559A CL2015000559A1 CL 2015000559 A1 CL2015000559 A1 CL 2015000559A1 CL 2015000559 A CL2015000559 A CL 2015000559A CL 2015000559 A CL2015000559 A CL 2015000559A CL 2015000559 A1 CL2015000559 A1 CL 2015000559A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- indoles
- schizophrenia
- parkinson
- alzheimer
- Prior art date
Links
- 208000011117 substance-related disease Diseases 0.000 title 2
- 208000007848 Alcoholism Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010013663 drug dependence Diseases 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 201000009032 substance abuse Diseases 0.000 title 1
- 231100000736 substance abuse Toxicity 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12184249 | 2012-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000559A1 true CL2015000559A1 (es) | 2015-07-10 |
Family
ID=47044777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000559A CL2015000559A1 (es) | 2012-09-13 | 2015-03-06 | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9221816B2 (es) |
| EP (1) | EP2895476B1 (es) |
| JP (1) | JP6116693B2 (es) |
| KR (1) | KR101706877B1 (es) |
| CN (1) | CN104619701B (es) |
| AR (1) | AR092555A1 (es) |
| AU (1) | AU2013314417B2 (es) |
| BR (1) | BR112015005186A2 (es) |
| CA (1) | CA2883817C (es) |
| CL (1) | CL2015000559A1 (es) |
| CR (1) | CR20150084A (es) |
| EA (1) | EA027176B1 (es) |
| ES (1) | ES2590531T3 (es) |
| IL (1) | IL237266A0 (es) |
| MA (1) | MA37943B1 (es) |
| MX (1) | MX2015003330A (es) |
| PE (1) | PE20150943A1 (es) |
| PH (1) | PH12015500400A1 (es) |
| SG (1) | SG11201501923WA (es) |
| TW (1) | TWI490213B (es) |
| WO (1) | WO2014040969A1 (es) |
| ZA (1) | ZA201501262B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101811549B1 (ko) * | 2013-06-19 | 2017-12-26 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체 |
| MX374574B (es) * | 2014-05-22 | 2025-03-06 | Hoffmann La Roche | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. |
| AU2015279377B2 (en) * | 2014-06-26 | 2019-09-12 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
| WO2017076931A1 (en) | 2015-11-06 | 2017-05-11 | F. Hoffmann-La Roche Ag | Indolin-2-one derivatives for use in the treatment of cns and related disorders |
| PH12018500978B1 (en) * | 2015-11-06 | 2023-05-05 | Hoffmann La Roche | Indolin-2-one derivatives |
| EP3371170B1 (en) | 2015-11-06 | 2019-07-31 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives useful in the treatment of cns diseases |
| CN108137561B (zh) | 2015-11-06 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
| CN106065008B (zh) * | 2016-06-16 | 2018-06-05 | 黑龙江中医药大学 | 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用 |
| GB201709456D0 (en) * | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN119866338A (zh) * | 2022-06-23 | 2025-04-22 | 渤健马萨诸塞州股份有限公司 | 酪氨酸激酶2抑制剂及其用途 |
| CN116640083A (zh) * | 2023-05-30 | 2023-08-25 | 江苏海洋大学 | 一种gpr52调节剂化合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR851085B (es) | 1984-05-12 | 1985-11-25 | Boehringer Mannheim Gmbh | |
| DE3417643A1 (de) | 1984-05-12 | 1985-11-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte |
| DE3445669A1 (de) | 1984-12-14 | 1986-06-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3501497A1 (de) | 1985-01-18 | 1986-07-24 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte |
| US4835280A (en) | 1985-01-18 | 1989-05-30 | Boehringer Mannheim Gmbh | Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles |
| DE3803775A1 (de) | 1988-02-09 | 1989-08-17 | Boehringer Mannheim Gmbh | Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| DE3818830A1 (de) | 1988-06-03 | 1989-12-14 | Boehringer Mannheim Gmbh | Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel |
| DE3925584A1 (de) * | 1989-08-02 | 1991-02-07 | Boehringer Mannheim Gmbh | Neue n-(dimethyloxophosphinylmethyl-)-lactame, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| CA2383623A1 (en) | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
| EP1165513A1 (en) | 1999-03-24 | 2002-01-02 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
| CN100562513C (zh) * | 2003-06-12 | 2009-11-25 | 安斯泰来制药有限公司 | 苯甲酰胺衍生物或其盐 |
| US7585878B2 (en) * | 2003-06-12 | 2009-09-08 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| ZA200703912B (en) | 2004-10-20 | 2008-09-25 | Serono Lab | 3-arylamino pyridine derivatives |
| US20060142247A1 (en) | 2004-12-17 | 2006-06-29 | Guy Georges | Tricyclic heterocycles |
| CA2629964A1 (en) | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
| CN101765425A (zh) * | 2007-08-02 | 2010-06-30 | 弗·哈夫曼-拉罗切有限公司 | 苯甲酰胺衍生物用于治疗cns障碍的用途 |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
| WO2012064744A2 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
-
2013
- 2013-09-10 KR KR1020157009290A patent/KR101706877B1/ko not_active Expired - Fee Related
- 2013-09-10 ES ES13759241.6T patent/ES2590531T3/es active Active
- 2013-09-10 SG SG11201501923WA patent/SG11201501923WA/en unknown
- 2013-09-10 EP EP13759241.6A patent/EP2895476B1/en active Active
- 2013-09-10 CN CN201380047631.2A patent/CN104619701B/zh active Active
- 2013-09-10 JP JP2015531533A patent/JP6116693B2/ja active Active
- 2013-09-10 CA CA2883817A patent/CA2883817C/en not_active Expired - Fee Related
- 2013-09-10 WO PCT/EP2013/068668 patent/WO2014040969A1/en not_active Ceased
- 2013-09-10 PE PE2015000365A patent/PE20150943A1/es not_active Application Discontinuation
- 2013-09-10 EA EA201590438A patent/EA027176B1/ru not_active IP Right Cessation
- 2013-09-10 MX MX2015003330A patent/MX2015003330A/es unknown
- 2013-09-10 BR BR112015005186A patent/BR112015005186A2/pt not_active IP Right Cessation
- 2013-09-10 AU AU2013314417A patent/AU2013314417B2/en not_active Ceased
- 2013-09-12 TW TW102133020A patent/TWI490213B/zh not_active IP Right Cessation
- 2013-09-13 AR ARP130103279A patent/AR092555A1/es unknown
-
2015
- 2015-02-16 IL IL237266A patent/IL237266A0/en unknown
- 2015-02-19 CR CR20150084A patent/CR20150084A/es unknown
- 2015-02-24 ZA ZA2015/01262A patent/ZA201501262B/en unknown
- 2015-02-24 PH PH12015500400A patent/PH12015500400A1/en unknown
- 2015-03-06 CL CL2015000559A patent/CL2015000559A1/es unknown
- 2015-03-11 US US14/645,033 patent/US9221816B2/en active Active
- 2015-03-20 MA MA37943A patent/MA37943B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2883817C (en) | 2017-09-05 |
| CN104619701A (zh) | 2015-05-13 |
| PE20150943A1 (es) | 2015-06-20 |
| US9221816B2 (en) | 2015-12-29 |
| CA2883817A1 (en) | 2014-03-20 |
| ZA201501262B (en) | 2016-03-30 |
| AR092555A1 (es) | 2015-04-22 |
| AU2013314417B2 (en) | 2016-01-21 |
| SG11201501923WA (en) | 2015-04-29 |
| PH12015500400A1 (en) | 2015-04-27 |
| IL237266A0 (en) | 2015-04-30 |
| MA37943B1 (fr) | 2016-11-30 |
| EP2895476A1 (en) | 2015-07-22 |
| WO2014040969A1 (en) | 2014-03-20 |
| JP2015529673A (ja) | 2015-10-08 |
| KR101706877B1 (ko) | 2017-02-15 |
| EA201590438A1 (ru) | 2015-06-30 |
| EA027176B1 (ru) | 2017-06-30 |
| JP6116693B2 (ja) | 2017-04-19 |
| US20150284386A1 (en) | 2015-10-08 |
| AU2013314417A1 (en) | 2015-03-05 |
| MA37943A1 (fr) | 2016-04-29 |
| TWI490213B (zh) | 2015-07-01 |
| BR112015005186A2 (pt) | 2017-07-04 |
| CR20150084A (es) | 2015-04-06 |
| EP2895476B1 (en) | 2016-06-22 |
| HK1206721A1 (en) | 2016-01-15 |
| TW201416358A (zh) | 2014-05-01 |
| CN104619701B (zh) | 2016-10-19 |
| KR20150054991A (ko) | 2015-05-20 |
| ES2590531T3 (es) | 2016-11-22 |
| MX2015003330A (es) | 2015-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000559A1 (es) | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. | |
| CL2016001983A1 (es) | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
| UY35628A (es) | ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?. | |
| CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| CL2014002732A1 (es) | Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras. | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| CL2014000171A1 (es) | Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras. | |
| CL2008002809A1 (es) | Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros. | |
| CL2014002847A1 (es) | Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. | |
| CL2015000717A1 (es) | Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c. | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| UY35129A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| SV2016005306A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CL2013002394A1 (es) | Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| MX385382B (es) | Compuestos y metodos. | |
| DOP2016000289A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CL2015001615A1 (es) | Una composicion farmaceutica que comprende vortioxetina y donepezilo junto con un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de disfuncion cognitiva, demencia en la enfermedad de alzheimer, disfuncion cognitiva asociada a la depresion y a la esquizofrenia, entre otras enfermedades. |